Immunomodulatory Treatment of Lyell’s Syndrome: A Simultaneous Plasmapheresis and Intravenous Immunoglobulins Therapy
- 9 April 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 43 (6) , 1394-1398
Abstract
Lyell’s syndrome, or toxic epidermal necrolysis (TEN) is a rare but life-threatening condition. It manifests with blistering of skin and mucous due to subepidermal bullae and keratinocyte necrosis. In most cases, it is an immune response to drugs or their metabolites. The mortality in TEN is high despite optimal infection and wound control. There are no unequivocal treatment guidelines in TEN. Immunosuppressive treatment may increase the wound infection risk and mortality. The aim of the study was to evaluate a 10-year experience with immunomodulatory therapy in TEN. We perform a combination of plasmapheresis and intravenous immunoglobulins to control the disease. There were 35 patients in the group and we performed a post hoc evaluation. Twenty-eight patients received the full protocol and there were seven patients who did not complete the treatment (single therapy group). The mortality in the test group was 14.29%, and the difference reached statistical significance in comparison with the single therapy group (P < .05). Our protocol reduced the mortality risk five times. Our study proved that simultaneous plasmaphereses with intravenous immunoglobulins administration were safe and improved patients’ outcome in TEN.Keywords
This publication has 20 references indexed in Scilit:
- A review of toxic epidermal necrolysis management in JapanAllergology International, 2017
- Nine years of a single referral center management of Stevens–Johnson syndrome and toxic epidermal necrolysis (Lyell’s syndrome)Cutaneous and Ocular Toxicology, 2016
- Powikłania u chorych leczonych metodą plazmaferezy na oddziale intensywnej terapiiAnaesthesiology Intensive Therapy, 2013
- The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysisBritish Journal of Dermatology, 2012
- Efficacy of plasmapheresis for the treatment of severe toxic epidermal necrolysis: Is cytokine expression analysis useful in predicting its therapeutic efficacy?The Journal of Dermatology, 2011
- Beneficial Therapeutic Effect of Plasmapheresis After Unsuccessful Treatment With Corticosteroids in Two Patients With Severe Toxic Epidermal NecrolysisTherapeutic Apheresis and Dialysis, 2010
- Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary reportBritish Journal of Plastic Surgery, 2005
- Intravenous Immunoglobulin Treatment for Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisArchives of Dermatology, 2003
- Plasmapheresis as an adjunct treatment in toxic epidermal necrolysisJournal of the American Academy of Dermatology, 1999
- Plasmapheresis in toxic epidermal necrolysisInternational Journal of Dermatology, 1997